// App-Quantinova.ai

: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease

Researchers

Presenter

  • NIKOLAUS MARX

Principal Investigators

  • DARREN K. MCGUIRE

  • ODD ERIK JOHANSEN

  • JULIO ROSENSTOCK

  • STEVEN E. KAHN

  • MARK E. COOPER

  • ROBERT D. TOTO

  • CHRISTOPH WANNER

  • EGON PFARR

  • SVEN SCHNAIDT

  • JYOTHIS GEORGE

  • MAXIMILIAN VON EYNATTEN

  • VLADO PERKOVIC

  • BERNARD ZINMAN

Medical Centers

  • N/A

Locations

  • Germany

  • United States

  • Norway

  • Australia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Coronary Artery Disease

  • Type 2 diabetes mellitus

  • Congestive heart failure

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • Linagliptin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved